Literature DB >> 21242060

Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention?

Vivek H Phutane1, Cenk Tek, Lydia Chwastiak, Joseph C Ratliff, Banu Ozyuksel, Scott W Woods, Vinod H Srihari.   

Abstract

OBJECTIVE: Studies in first episode psychosis samples about status of cardiovascular risk factors have shown discordant results. We aimed to determine the 10-year risk of developing coronary heart disease in a sample of first episode psychosis patients referred to an early intervention clinic and compared the same with age, gender, and race matched controls from the U.S. National Health and Nutrition Examination Survey (NHANES).
METHOD: We conducted a cross-sectional analysis of baseline data of 56 subjects enrolled in first episode psychosis clinic from April 2006 to January 2010. This sample was compared with age, gender, and race matched 145 individuals drawn from NHANES 2005-2006 database. Sociodemographic and clinical variables were collected. Physical examination including laboratory evaluation was used to screen for common medical illnesses. The 10-year risk of developing coronary heart disease was calculated by using a tool developed by the National Cholesterol Education Program (NCEP-ATP III).
RESULTS: There were elevated rates of smoking (46%) and hypertension (11%) albeit statistically significant differences from the control could not be demonstrated for these measures or weight, body mass index, or total or HDL cholesterol, fasting plasma glucose, status of diabetes and impaired fasting plasma glucose, HbA1C level. The 10-year median (range) risk of developing coronary heart disease in patients and controls was 1 (0-5)% and 0 (0-9)% respectively. The difference was not statistically significant.
CONCLUSIONS: First episode psychosis patients do not present with significantly higher cardiovascular risk than age and race-matched controls despite clinically significant prevalence of individual risk factors. This sample presents an opportunity for early intervention for the primary prevention of cardiovascular morbidity and mortality.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21242060      PMCID: PMC3051021          DOI: 10.1016/j.schres.2010.12.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  40 in total

1.  Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use.

Authors:  Jose de Leon
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

2.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 3.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

4.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 5.  Weight gain in antipsychotic-naive patients: a review and meta-analysis.

Authors:  I Tarricone; B Ferrari Gozzi; A Serretti; D Grieco; D Berardi
Journal:  Psychol Med       Date:  2009-08-06       Impact factor: 7.723

6.  Serious cardiovascular events and mortality among patients with schizophrenia.

Authors:  Cheryl Enger; Lisa Weatherby; Robert F Reynolds; Dale B Glasser; Alexander M Walker
Journal:  J Nerv Ment Dis       Date:  2004-01       Impact factor: 2.254

7.  Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

Authors:  Martina C M Ryan; Patrick Collins; Jogin H Thakore
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

8.  A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Authors:  Rocio Perez-Iglesias; Benedicto Crespo-Facorro; Jose Antonio Amado; Maria Teresa Garcia-Unzueta; Maria Luz Ramirez-Bonilla; Cesar Gonzalez-Blanch; Obdulia Martinez-Garcia; Jose Luis Vazquez-Barquero
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

9.  Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database.

Authors:  David P J Osborn; Gus Levy; Irwin Nazareth; Irene Petersen; Amir Islam; Michael B King
Journal:  Arch Gen Psychiatry       Date:  2007-02

10.  Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.

Authors:  Craig W Colton; Ronald W Manderscheid
Journal:  Prev Chronic Dis       Date:  2006-03-15       Impact factor: 2.830

View more
  23 in total

1.  Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.

Authors:  Joseph C Ratliff; Laura B Palmese; Erin L Reutenauer; Vinod H Srihari; Cenk Tek
Journal:  Psychosomatics       Date:  2012-06-02       Impact factor: 2.386

2.  The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional study.

Authors:  Joseph C Ratliff; Laura B Palmese; Erin L Reutenauer; Ellen Liskov; Carlos M Grilo; Cenk Tek
Journal:  Compr Psychiatry       Date:  2012-03-16       Impact factor: 3.735

3.  Insomnia is frequent in schizophrenia and associated with night eating and obesity.

Authors:  Laura B Palmese; Pamela C DeGeorge; Joseph C Ratliff; Vinod H Srihari; Bruce E Wexler; Andrew D Krystal; Cenk Tek
Journal:  Schizophr Res       Date:  2011-12       Impact factor: 4.939

4.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

5.  Cardiovascular mortality in schizophrenia: defining a critical period for prevention.

Authors:  Vinod H Srihari; Vivek H Phutane; Banu Ozkan; Lydia Chwastiak; Joseph C Ratliff; Scott W Woods; Cenk Tek
Journal:  Schizophr Res       Date:  2013-02-17       Impact factor: 4.939

Review 6.  Is early intervention for psychosis feasible and effective?

Authors:  Vinod H Srihari; Jai Shah; Matcheri S Keshavan
Journal:  Psychiatr Clin North Am       Date:  2012-07-21

Review 7.  Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.

Authors:  Alex J Mitchell; Davy Vancampfort; Amber De Herdt; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

8.  A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.

Authors:  Cenk Tek; Joseph Ratliff; Erin Reutenauer; Rohan Ganguli; Stephanie S O'Malley
Journal:  J Clin Psychopharmacol       Date:  2014-10       Impact factor: 3.153

9.  The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service.

Authors:  Nicholas J K Breitborde; Emily K Bell; David Dawley; Cindy Woolverton; Alan Ceaser; Allison C Waters; Spencer C Dawson; Andrew W Bismark; Angelina J Polsinelli; Lisa Bartolomeo; Jessica Simmons; Beth Bernstein; Patricia Harrison-Monroe
Journal:  BMC Psychiatry       Date:  2015-10-28       Impact factor: 3.630

Review 10.  Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management.

Authors:  Antonio Ventriglio; Alessandro Gentile; Eleonora Stella; Antonello Bellomo
Journal:  Front Neurosci       Date:  2015-09-03       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.